Last reviewed · How we verify
Seasonal trivalent influenza vaccine, Anflu®
The vaccine stimulates the immune system to produce antibodies and cellular immunity against three seasonal influenza virus strains.
The vaccine stimulates the immune system to produce antibodies and cellular immunity against three seasonal influenza virus strains. Used for Prevention of seasonal influenza caused by influenza A and B viruses.
At a glance
| Generic name | Seasonal trivalent influenza vaccine, Anflu® |
|---|---|
| Also known as | Anflu® |
| Sponsor | Center for Disease Prevention and Control of Beijing Military Region |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Seasonal trivalent influenza vaccines contain inactivated or attenuated viral antigens from three circulating influenza strains (typically two A subtypes and one B type). Upon administration, the vaccine triggers both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and neutralize these specific influenza viruses if encountered naturally, thereby preventing infection or reducing disease severity.
Approved indications
- Prevention of seasonal influenza caused by influenza A and B viruses
Common side effects
- Injection site pain, redness, or swelling
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military (PHASE4)
- The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: